<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39389075</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(24)00615-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(24)00615-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumagai</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanai</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwama</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okura</LastName><ForeName>Iori</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minamida</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagi</LastName><ForeName>Yukihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosawa</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chivukula</LastName><ForeName>Pad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Arcturus Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Arcturus Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walson</LastName><ForeName>Judd L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Walson Consulting LLC, Seattle, WA 98117, USA. Electronic address: jwalson@walsonconsultingllc.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Infect Dis. 2024 Oct 18:S1473-3099(24)00721-7. doi: 10.1016/S1473-3099(24)00721-7</RefSource><PMID Version="1">39433050</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>TK is a board member and stockholder of Meiji Seika Pharma. YO, MK, YI, IO, TM, and YY are full-time employees of Meiji Seika Pharma. YK received consulting fees from Meiji Seika Pharma. PC and YZ are full-time employees at Arcturus Therapeutics with stock options. JLW received consulting fees from Arcturus Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39389075</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(24)00615-7</ArticleId><ArticleId IdType="pii">S1473-3099(24)00615-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle>